Sandbox vidit: Difference between revisions

Jump to navigation Jump to search
Line 45: Line 45:
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Female gender'''''<BR>▸ '''''Age 65-74 years'''''<BR> ▸ '''''[[Coronary artery disease]]'''''<BR>▸ '''''[[Thyrotoxicosis]]'''''|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''Age ≥ 75 years'''''<BR>▸ '''''[[Hypertension]]'''''<BR> ▸ '''''[[Heart failure]]'''''<BR>▸ '''''LV [[ejection fraction]] ≤ 35%'''''<BR>▸ '''''[[Diabetes mellitus]]''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''Previous [[stroke]], [[TIA]] or [[embolism]]'''''<BR>▸ '''''[[Mitral stenosis]]'''''<BR> ▸ '''''[[Prosthetic heart valve]]'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Female gender'''''<BR>▸ '''''Age 65-74 years'''''<BR> ▸ '''''[[Coronary artery disease]]'''''<BR>▸ '''''[[Thyrotoxicosis]]'''''|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''Age ≥ 75 years'''''<BR>▸ '''''[[Hypertension]]'''''<BR> ▸ '''''[[Heart failure]]'''''<BR>▸ '''''LV [[ejection fraction]] ≤ 35%'''''<BR>▸ '''''[[Diabetes mellitus]]''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''Previous [[stroke]], [[TIA]] or [[embolism]]'''''<BR>▸ '''''[[Mitral stenosis]]'''''<BR> ▸ '''''[[Prosthetic heart valve]]'''''
|-
|-
|}
===Antiarrhythmic Therapy===
{| style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center; colspan="2"| {{fontcolor|#FFF|Maintenance of Sinus Rhythm}}
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] (100 to 400 mg)'''''<BR>''OR''<BR>▸ '''''[[Disopyramide]] (400 to 750 mg)'''''<BR>''OR''<BR> ▸ '''''[[Dofetilide]] (500 to 1000 mcg)'''''<BR>''OR''<BR>▸ '''''[[Flecainide]] (200 to 300 mg)'''''<BR>''OR''<BR>▸ '''''[[Procainamide]] (1000 to 4000 mcg)'''''<BR>''OR''<BR>▸ '''''[[Propafenone]] (450 to 900 mg)'''''<BR>''OR''<BR>▸ '''''[[Quinidine]] (600 to 1500 mg)'''''<BR>''OR''<BR>▸ '''''[[Sotalol]] (160 to 320 mg)'''''
|-
|}
|}
|}

Revision as of 19:25, 10 March 2014

 
 
 
 
 
 
Atrial flutter
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unstable
 
 
 
 
 
Stable
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Look for the presence of any of these:
❑ Chronic heart failure
❑ Hypotension
❑ Acute myocardial infarction
 
 
 
 
 
❑ Administer anticoagulation therapy based on the risk of stroke, if total duration of flutter > 48 hours
❑ Administer rate control therapy (AV nodal blockers)

THEN

❑ Attempt conversion
❑ DC cardioversion
❑ Atrial pacing
❑ Pharmacological cardioversion
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Assess need for therapy to prevent recurrence
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Administer antiarrythmic therapy to prevent recurrences
❑ Consider catheter ablation if antiarrhythmic therapy fails
 
 
 
 
 
 
 
 
 
 

Anticoagulation Therapy

Shown below are tables depicting the assessment of risk of stroke and the appropriate anticoagulation therapy among patients with Atrial flutter.[1]

Anticoagulation Therapy
No risk factors Aspirin 81-325 mg daily
1 Moderate risk factor Aspirin 81-325 mg daily
OR
Warfarin (INR 2.0 to 3.0, target 2.5)
Any high risk factor or
more than 1 moderate risk factor
Warfarin (INR 2.0 to 3.0, target 2.5)


Low Risk Factors Moderate Risk Factors High Risk Factors
Female gender
Age 65-74 years
Coronary artery disease
Thyrotoxicosis
Age ≥ 75 years
Hypertension
Heart failure
LV ejection fraction ≤ 35%
Diabetes mellitus
Previous stroke, TIA or embolism
Mitral stenosis
Prosthetic heart valve
  1. Fuster, V.; Rydén, LE.; Cannom, DS.; Crijns, HJ.; Curtis, AB.; Ellenbogen, KA.; Halperin, JL.; Kay, GN.; Le Huezey, JY. (2011). "2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines". Circulation. 123 (10): e269–367. doi:10.1161/CIR.0b013e318214876d. PMID 21382897. Unknown parameter |month= ignored (help)